Focus on Approved and In-Clinical-Trial Monoclonal Antibodies

Total Page:16

File Type:pdf, Size:1020Kb

Focus on Approved and In-Clinical-Trial Monoclonal Antibodies Journal name: Drug Design, Development and Therapy Article Designation: Review Year: 2017 Volume: 11 Drug Design, Development and Therapy Dovepress Running head verso: Françoso and Simioni Running head recto: Monoclonal antibodies to colorectal tumors open access to scientific and medical research DOI: http://dx.doi.org/10.2147/DDDT.S119036 Open Access Full Text Article REVIEW Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies Alex Françoso1 Abstract: Colorectal cancer is considered a disease of the elderly population. Since the number Patricia Ucelli Simioni1–3 of geriatric patients continues to rise, monoclonal antibody therapy is the most promising therapy in the recent research. Presently, the monoclonal antibodies most frequently used in the 1Department of Biomedical Science, Faculty of Americana, Americana, treatment of colorectal tumors are bevacizumab, cetuximab, panitumumab, and ramucirumab. 2Department of Genetics, Evolution Bevacizumab is a monoclonal antibody that acts on VEGF. Cetuximab and panitumumab act and Bioagents, Institute of Biology, University of Campinas, Campinas, on EGFR. Ramucirumab binds directly to the ligand-binding pocket of VEGFR-2 to block 3Department of Biochemistry and the binding of VEGF-A, VEGF-C, and VEGF-D. These monoclonal antibodies, alone or in Microbiology, Institute of Biosciences, association with radiotherapy or chemotherapy, are presenting good results and are increasing Universidade Estadual Paulista, Rio Claro, São Paulo, Brazil patient survival, despite the side effects. Due to the limited number of molecules available, For personal use only. several studies are trying to develop new monoclonal antibodies for the treatment of colorec- tal tumors. Among those being studied, some recent molecules are in phase I and/or II trials and are yielding advantageous results, such as anti-DR5, anti-Fn14, anti-IGF-1R, anti-EGFR, anti-NRP1, and anti-A33 antibodies. This has been successful in reducing side effects and in treating nonresponsive patients. Keywords: monoclonal antibodies, colorectal tumor, bevacizumab, cetuximab, panitumumab, ramucirumab Colorectal tumor Colorectal cancer is considered a heterogeneous disease, both in relation to the pathogenesis and the clinical signals.1 The incidence of colorectal cancer is higher in people between 60 and 70 years of age. Twenty percent of cases occur before the Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 18-Dec-2018 age of 50. Colorectal cancer is more prevalent in the US, Canada, Australia, New Zealand, Denmark, Sweden, and other developed countries. The incidence is 30 times lower in India, South America, and Africa. In Japan, the incidence is increas- ing gradually, reaching similar rates in the UK, presumably as a result of changes in lifestyle and diet.2–7 The discovery of sequences of genes associated with adenoma–carcinoma has contributed to understanding the genetic and epigenetic alterations that drive the for- mation of colorectal cancer. Among the genetic alterations associated with colorectal cancer, abnormal activation of the Wnt/β-catenin signaling pathway has an important role, because Wnt pathway is crucial in cell proliferation and migration.8 Correspondence: Patricia Ucelli Simioni Somatic mutations may play an important role as prognostic or predictive mark- Faculdade de Americana, FAM, Rua Joaquim Boer, 733, Jardim Luciene, ers for the development of specific therapies in colorectal cancer. These mutations 13477-360, Americana, São Paulo, Brazil involve genes such as KRAS, BRAF, PIK3CA, AKT1, PTEN, NRAS, and TGFBR2.9–15 Tel +55 19 9 9699 1899 Email [email protected] Therefore, epigenetic and gene silencing events may increase the progression of submit your manuscript | www.dovepress.com Drug Design, Development and Therapy 2017:11 177–184 177 Dovepress © 2017 Françoso and Simioni. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you http://dx.doi.org/10.2147/DDDT.S119036 hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Powered by TCPDF (www.tcpdf.org) 1 / 1 Françoso and Simioni Dovepress colorectal cancer.16 This finding opens new possibilities regions. It recognizes the extracellular domain of the EGFR for high-precision laboratory tests such as the identification and therefore can block the tumor growth.47 of molecular markers in screening tests for noninvasive After binding to the extracellular domain of EGFR, this colorectal adenocarcinoma.17 antibody prevents the signaling and ligand-induced dimeriza- tion of the receptor. In this way, it blocks the signals of cell Supporting treatment with growth and tumor survival. Cetuximab may have the function monoclonal antibodies of mediating antibody-dependent cellular cytotoxicity Approved monoclonal antibodies (ADCC). This monoclonal antibody only achieves dynamic for therapy equilibrium after the third week of infusion.48–56 In addition, Several monoclonal antibodies for different therapeutic this biological molecule was approved by the US Food and targets have already been approved for use in patients with Drug Administration (FDA) for patients with metastatic tumors. For example, cetuximab and panitumumab are mono- colorectal cancer (mCRC), especially for patients who do not clonal antibodies directed at the EGFR.4,18,19 Bevacizumab is tolerate irinotecan (a chemotherapeutic drug), and was also targeted to the VEGF.20,21 Ramucirumab inhibits VEGF and associated with irinotecan for patients who do not tolerate 57,58 VEGF receptor.22,23 Moreover, for the CD20 target, rituximab, oxaliplatin, irinotecan, and 5-fluorouracil (5-FU). ofatumumab, tositumomab, and ibritumomab tiuxetan24–26 are Some patients present an anaphylactic reaction. A study used. The antibodies trastuzumab, pertuzumab, trastuzumab, has shown that there is a higher incidence of anaphylaxis and emtansine are directed HER2/neu.27–33 The monoclonal in people who have a history of allergies to red meat and 59 antibody that targets the CD33 molecule is gemtuzumab tick bites. Cutaneous reactions are considered severe with ozogamicin.31,34 Alemtuzumab binds to CD52,35,36 while cetuximab. Cytokine release syndrome occurs usually 1 hour brentuximab vedotin is directed at the CD30 molecule.37 after the infusion. This reaction is usually more severe after 60 Ipilimumab binds to the CTLA4 molecule, among others.38,39 the first infusion. Electrolyte disturbances and neutropenia events may be related to the associated chemotherapy using For personal use only. Still under development are monoclonal antibodies directed at new or older potential targets, but are not yet approved for platinum-based compounds. Eye infections such as ulcerative 61 use in patients.18,25,40–43 dermatitis can also occur. Cetuximab has demonstrated benefits only in a small Approved monoclonal antibodies for subset of metastatic patients (KRAS wild-type patients colorectal tumors and patients with limited metastatic disease). Alterna- At present, among biological molecules, a few antibodies tive strategies that demonstrate promising results for have their use approved for the treatment of colorectal tumors the treatment of rectal cancer during stage II/III include (Table 1). The four approved monoclonal antibodies showing short-course radiotherapy with adjuvant chemotherapy and favorable results for use in the treatment of colorectal cancer neoadjuvant FOLFOX (folinic acid, 5-FU, and oxaliplatin)– 62 are bevacizumab, cetuximab, panitumumab, and ramuci- bevacizumab without radiotherapy. rumab, which are detailed in the following section.42,44–46 Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 18-Dec-2018 Panitumumab Cetuximab Panitumumab is a humanized IgG2 kappa antibody with com- Cetuximab is a monoclonal antibody, IgG1 kappa human/ plementary determining regions (CDRs) of murine origin. It is murine chimeric, with constant regions and murine variable directed against the EGFR. When compared with cetuximab, Table 1 Approved antibodies for the treatment of colorectal tumor Monoclonal antibody Therapeutic target Mechanism of action Indication approved (FDA) Bevacizumab VEGF Inhibition of VEGF Colorectal cancer – palliative treatment (humanized IgG1) Cetuximab (humanized/ EGFR (ErbB1) Inhibition of EGFR; ADCC Colorectal cancer – palliative treatment murine chimeric IgG1) Panitumumab EGFR Inhibition of EGFR Metastatic colorectal carcinoma – with EGFR expression Ramucirumab VEGF receptor-2 Blockage of VEGF-A, VEGF-C, mCRC – in combination with FOLFIRI and binding of VEGF-D (irinotecan, folinic acid, and 5-fluorouracil) Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; FDA, US Food and Drug Administration; mCRC, metastatic colorectal cancer. 178 submit your manuscript | www.dovepress.com Drug Design, Development and Therapy 2017:11 Dovepress Powered by TCPDF (www.tcpdf.org) 1 / 1 Dovepress Monoclonal antibodies to colorectal tumors it is a murine
Recommended publications
  • HER2 Inhibition in Gastro-Oesophageal Cancer: a Review Drawing on Lessons Learned from Breast Cancer
    Submit a Manuscript: http://www.f6publishing.com World J Gastrointest Oncol 2018 July 15; 10(7): 159-171 DOI: 10.4251/wjgo.v10.i7.159 ISSN 1948-5204 (online) REVIEW HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer Hazel Lote, Nicola Valeri, Ian Chau Hazel Lote, Nicola Valeri, Centre for Molecular Pathology, Accepted: May 30, 2018 Institute of Cancer Research, Sutton SM2 5NG, United Kingdom Article in press: May 30, 2018 Published online: July 15, 2018 Hazel Lote, Nicola Valeri, Ian Chau, Department of Medicine, Royal Marsden Hospital, Sutton SM2 5PT, United Kingdom ORCID number: Hazel Lote (0000-0003-1172-0372); Nicola Valeri (0000-0002-5426-5683); Ian Chau (0000-0003-0286-8703). Abstract Human epidermal growth factor receptor 2 (HER2)- Author contributions: Lote H wrote the original manuscript and revised it following peer review comments; Valeri N reviewed inhibition is an important therapeutic strategy in HER2- the manuscript; Chau I reviewed and contributed to the content of amplified gastro-oesophageal cancer (GOC). A significant the manuscript. proportion of GOC patients display HER2 amplification, yet HER2 inhibition in these patients has not displayed Supported by National Health Service funding to the National the success seen in HER2 amplified breast cancer. Mu- Institute for Health Research Biomedical Research Centre at ch of the current evidence surrounding HER2 has been the Royal Marsden NHS Foundation Trust and The Institute of obtained from studies in breast cancer, and we are only re- Cancer Research, No. A62, No. A100, No. A101 and No. A159; Cancer Research UK funding, No.
    [Show full text]
  • Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics in Vivo by Humanized Monoclonal Antibody CS-1008
    Published OnlineFirst September 17, 2013; DOI: 10.1158/1078-0432.CCR-12-3104 Clinical Cancer Imaging, Diagnosis, Prognosis Research Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics In Vivo by Humanized Monoclonal Antibody CS-1008 Ingrid J.G. Burvenich1, Fook T. Lee1, Glenn A. Cartwright1, Graeme J. O'Keefe3, Dahna Makris1, Diana Cao1, Sylvia Gong3, Anderly C. Chueh2, John M. Mariadason2, Martin W. Brechbiel4, Robert A. Beckman5, Kosaku Fujiwara6, Reinhard von Roemeling5, and Andrew M. Scott1,3 Abstract Purpose: CS-1008 (tigatuzumab; phase I/II), an antihuman death receptor 5 (DR5) agonist, induces apoptosis and has cytotoxic activity against human cancer cell lines. This study reports on the preclinical validation of 111In-labeled anti-DR5 humanized antibody CS-1008 as a diagnostic tool to study the DR5 occupancy in patients with cancer and establish dose ranges for receptor saturation kinetics in vivo. Experimental Design: CS-1008 was radiolabeled and characterized for DR5 binding and labeling efficiency on TRAIL-sensitive DR5–positive colorectal cancer cells (COLO 205 and WiDr). Pharmacokinetic and biodistribution studies were conducted in BALB/c nu/nu mice bearing COLO 205, WiDr, or DR5- negative CT26 colon tumors. Planar gamma camera imaging and computerized tomography (CT) images were obtained to study receptor occupancy in vivo. 111 Results: Scatchard analysis showed high and specific binding affinity (Kd, 1.05 Æ 0.12 nmol/L) of In- labeled CS-1008. 111In-labeled CS-1008 was specifically taken up in mice bearing COLO 205 and WiDr tumors with prolonged tumor retention (26.25 Æ 2.85%ID/g vs.
    [Show full text]
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Etude Des Résistances Adaptatives Aux Inhibiteurs De Tyrosine Kinase De L’EGFR Dans Les Cancers Bronchiques
    Thèse d’exercice Faculté de Pharmacie Année 2020 Thèse N° MÉMOIRE DU DIPLÔME D'ÉTUDES SPÉCIALISÉES D’INNOVATION PHARMACEUTIQUE ET RECHERCHE TENANT LIEU DE THÈSE D’EXERCICE POUR LE DIPLÔME D’ÉTAT DE DOCTEUR ENPHARMACIE Présentée et soutenue publiquement le 24 septembre 2020 par Sarah FIGAROL Née le 19 septembre 1989 à Toulouse Etude des résistances adaptatives aux inhibiteurs de tyrosine kinase de l’EGFR dans les cancers bronchiques Thèse dirigée par Gilles Favre Examinateurs : M. Franck Saint-Marcoux, président du jury M.Gilles Favre, directeur de thèse M. Jean-Marie Canonge, juge M. Julien Mazières, juge M. Antonio Maraver, juge Thèse d’exercice Faculté de Pharmacie Année 2020 Thèse N° MÉMOIRE DU DIPLÔME D'ÉTUDES SPÉCIALISÉES D’INNOVATION PHARMACEUTIQUE ET RECHERCHE TENANT LIEU DE THÈSE D’EXERCICE POUR LE DIPLÔME D’ÉTAT DE DOCTEUR ENPHARMACIE Présentée et soutenue publiquement le 24 septembre 2020 par Sarah FIGAROL Née le 19 septembre 1989 à Toulouse Etude des résistances adaptatives aux inhibiteurs de tyrosine kinase de l’EGFR dans les cancers bronchiques Thèse dirigée par Gilles Favre Examinateurs : M. Franck Saint-Marcoux, président du jury M.Gilles Favre, directeur de thèse M. Jean-Marie Canonge, juge M. Julien Mazières, juge M. Antonio Maraver, juge Sarah FIGAROL | Thèse d’exercice | Université de Limoges |2020 3 Licence CC BY-NC-ND 3.0 Liste des enseignants Le 1er septembre 2019 PROFESSEURS : BATTU Serge CHIMIE ANALYTIQUE CARDOT Philippe CHIMIE ANALYTIQUE ET BROMATOLOGIE DESMOULIERE Alexis PHYSIOLOGIE DUROUX Jean-Luc BIOPHYSIQUE,
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • The Role of Biological Therapy in Metastatic Colorectal Cancer After First-Line Treatment: a Meta-Analysis of Randomised Trials
    REVIEW British Journal of Cancer (2014) 111, 1122–1131 | doi: 10.1038/bjc.2014.404 Keywords: colorectal; biological; meta-analysis The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials E Segelov1, D Chan*,2, J Shapiro3, T J Price4, C S Karapetis5, N C Tebbutt6 and N Pavlakis2 1St Vincent’s Clinical School, University of New South Wales, Sydney, NSW 2052, Australia; 2Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia; 3Monash University and Cabrini Hospital, Melbourne, VIC 3800, Australia; 4The Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA 5011, Australia; 5Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA, 5042, Australia and 6Austin Health, VIC 3084, Australia Purpose: Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy. Methods: Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s). Data were extracted on study design, participants, interventions and outcomes. Study quality was assessed using the MERGE criteria. Comparable data were pooled for meta-analysis. Results: Twenty eligible studies with 8225 patients were identified. The use of any biologic therapy improved overall survival with hazard ratio (HR) 0.87 (95% confidence interval (CI) 0.82–0.91, Po0.00001), progression-free survival (PFS) with HR 0.71 (95% CI 0.67–0.74, Po0.0001) and overall response rate (ORR) with odds ratio (OR) 2.38 (95% CI 2.03–2.78, Po0.00001).
    [Show full text]
  • Activating Death Receptor DR5 As a Therapeutic Strategy for Rhabdomyosarcoma
    International Scholarly Research Network ISRN Oncology Volume 2012, Article ID 395952, 10 pages doi:10.5402/2012/395952 Review Article Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma Zhigang Kang,1, 2 Shi-Yong Sun,3 and Liang Cao1 1 Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA 2 Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., NCI Frederick, Frederick, MD 21702, USA 3 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA Correspondence should be addressed to Liang Cao, [email protected] Received 4 January 2012; Accepted 24 January 2012 Academic Editors: E. Boven and S. Mandruzzato Copyright © 2012 Zhigang Kang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. It is believed to arise from skeletal muscle progenitors, preserving the expression of genes critical for embryonic myogenic development such as MYOD1 and myogenin. RMS is classified as embryonal, which is more common in younger children, or alveolar, which is more prevalent in elder children and adults. Despite aggressive management including surgery, radiation, and chemotherapy, the outcome for children with metastatic RMS is dismal, and the prognosis has remained unchanged for decades. Apoptosis is a highly regulated process critical for embryonic development and tissue and organ homeostasis. Like other types of cancers, RMS develops by evading intrinsic apoptosis via mutations in the p53 tumor suppressor gene.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • IGF System in Sarcomas: a Crucial Pathway with Many Unknowns to Exploit for Therapy
    61 1 Journal of Molecular C Mancarella and Targeting IGF system in sarcoma 61:1 T45–T60 Endocrinology K Scotlandi THEMATIC REVIEW 40 YEARS OF IGF1 IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy Caterina Mancarella and Katia Scotlandi Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Orthopaedic Rizzoli Institute, Bologna, Italy Correspondence should be addressed to K Scotlandi: [email protected] This paper forms part of a special section on 40 Years of IGF1. The guest editors for this section were Derek LeRoith and Emily Gallagher. Abstract The insulin-like growth factor (IGF) system has gained substantial interest due to its Key Words involvement in regulating cell proliferation, differentiation and survival during anoikis f sarcomas and after conventional and targeted therapies. However, results from clinical trials have f IGF system been largely disappointing, with only a few but notable exceptions, such as trials targeting f targeted therapy sarcomas, especially Ewing sarcoma. This review highlights key studies focusing on IGF f clinical trials signaling in sarcomas, specifically studies underscoring the properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited. This review discusses the potential roles of IGF2 mRNA-binding proteins (IGF2BPs), discoidin domain receptors (DDRs) and metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) in regulating the IGF system. Deeper investigation of these novel regulators of the IGF system may help us to further elucidate the spatial and temporal control of the IGF Journal of Molecular axis, as understanding the control of this axis is essential for future clinical studies.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH
    Published OnlineFirst February 2, 2010; DOI: 10.1158/1535-7163.MCT-09-0555 Research Article Molecular Cancer Therapeutics A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts Yaolin Wang1, Philip Lipari1, Xiaoying Wang1, Judith Hailey1, Lianzhu Liang1, Robert Ramos1, Ming Liu1, Jonathan A. Pachter2, W. Robert Bishop1, and Yan Wang1 Abstract The insulin-like growth factor-I receptor (IGF-IR) and its ligands (IGF-I and IGF-II) have been implicated in the growth, survival, and metastasis of a broad range of malignancies including pediatric tumors. Blocking the IGF-IR action is a potential cancer treatment. A fully human neutralizing monoclonal antibody, SCH 717454 (19D12, robatumumab), specific to IGF-IR, has shown potent antitumor effects in ovarian cancer in vitro and in vivo. In this study, SCH 717454 was evaluated in several pediatric solid tumors including neuroblastoma, osteosarcoma, and rhabdomyosarcoma. SCH 717454 is shown here to downregulate IGF-IR as well as inhibit IGF-IR and insulin receptor substrate-1 phosphorylation in pediatric tumor cells. IGF-IR and insulin receptor substrate-1 phosphorylation in the tumor cells. In vivo, SCH 717454 exhibits activity as a single agent and sig- nificantly inhibited growth of neuroblastoma, osteosarcoma, and rhabdomyosarcoma tumor xenografts. Combination of SCH 717454 with cisplatin or cyclophosphamide enhanced both the degree and the duration of the in vivo antitumor activity compared with single-agent treatments. Furthermore, SCH 717454 treatment markedly reduced Ki-67 expression and blood vessel formation in tumor xenografts, showing that the in vivo activity is derived from its inhibition of tumor cell proliferation and angiogenesis activity.
    [Show full text]
  • Therapeutic Targeting of the IGF Axis
    cells Review Therapeutic Targeting of the IGF Axis Eliot Osher and Valentine M. Macaulay * Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK * Correspondence: [email protected]; Tel.: +44-1865617337 Received: 8 July 2019; Accepted: 9 August 2019; Published: 14 August 2019 Abstract: The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging. Keywords: IGF; type 1 IGF receptor; IGF-1R; cancer; acromegaly; ophthalmopathy; IGF inhibitor 1. Introduction Insulin like growth factors (IGFs) are small (~7.5 kDa) ligands that play a critical role in many biological processes including proliferation and protection from apoptosis and normal somatic growth and development [1]. IGFs are members of a ligand family that includes insulin, a dipeptide comprised of A and B chains linked via two disulfide bonds, with a third disulfide linkage within the A chain.
    [Show full text]